WeTrials
Active, not recruiting

INTREPId (INTermediate Risk Erection PreservatIon Trial): A Randomized Trial of Radiation Therapy and Darolutamide for Prostate Cancer

What is this study?

This study is testing a new medication called darolutamide combined with radiation therapy for intermediate-risk prostate cancer. The main goal is to see if this new treatment works just as well as standard hormone therapy while helping to protect sexual health and erectile function.

Who can participate?

You might be able to join if you have been recently diagnosed with intermediate-risk prostate cancer and have not had prior surgeries or hormone treatments for it. Your healthcare team can review your specific PSA levels and medical history to check if you qualify.

What will happen?

Participants will receive radiation therapy along with hormone-blocking medications like darolutamide or standard options. You will be closely monitored by the study doctors throughout the process to track your health and recovery.

Where and when?

The study is taking place at medical centers in Stamford, Connecticut, and Boston, Massachusetts. While this study is currently active, it is not actively looking for new participants at this time.

Key Points
  • 1Tests a new hormone therapy called darolutamide with radiation
  • 2Aims to treat prostate cancer while protecting erectile function
  • 3Currently active but not enrolling new participants at this time

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Prostate Cancer

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.